cadisegliatin

Small molecule

Phase 3underway

Evidence outlook · registrational

Type 1 Diabetes: registrational readout pending

Its supporting mid-stage studies have completed. ClinicalTrials.gov estimates the registrational readout at 2027-04; company guidance (vTv Therapeutics, stated 2026-11-05): topline data expected mid-2027.

Company guidance: topline data expected mid-2027 (NCT06334133; vTv Therapeutics, 5 Nov 2026). “A total of 166 patients were randomized in the study and the Company expects to report topline results from the CATT1 study in mid-2027.” Source ↗

The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (1)
Type 1 Diabetes
Phase 2 (2)
Type 1 Diabetes
NCT07616206 · vTv Therapeutics
2026-09-29 – 2027-06 · Type 1 Diabetes (T1D)
What this study did
Other / comorbidity
NCT02405260 · vTv Therapeutics
2015-03 – 2016-09 · Diabetes Mellitus, Type 2
What this study did
Phase 1/2 (2)
Type 1 Diabetes
NCT03335371 · vTv Therapeutics
2017-10-25 – 2020-01-06 · Diabetes Mellitus, Type 1
What this study did
Other / comorbidity

Competitive landscape

4 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Type 1 Diabetes: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Cadisegliatin: this drugPhase 3Small moleculeGlucokinasenot yet gradedNo reviewed efficacy summary in this indication
AfrezzaApprovedPeptideInsulinPartial signal
NCT04974528: HbA1c change at week 26 (ITT, n=117 vs 113): Afrezza +0.19 vs rapid-acting insulin analog +0.01; difference 0.18 percentage points (95% CI -0.07 to 0.44); non-inferiority (0.4% margin) not met, one-sided adjusted p=0.058. missed
NCT01445951: Change in HbA1c from baseline to week 24 (LS mean): Technosphere Insulin (Gen2 inhaler) plus basal insulin -0.21% vs insulin aspart plus basal insulin -0.40%; difference 0.19% (95% CI 0.02 to 0.36), inside the pre-specified non-inferiority margin of 0.4% (CT.gov posted analysis).
Insulin Aspart (NovoLog)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Insulin Aspart (Fiasp)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Insulin Degludec (Tresiba)ApprovedPeptideInsulin receptor (basal)not yet gradedNo reviewed efficacy summary in this indication
Insulin Detemir (Levemir)
ApprovedUS marketing discontinued
PeptideInsulin receptor (basal)not yet gradedNo reviewed efficacy summary in this indication
Insulin Glargine (Lantus)ApprovedPeptideInsulin receptor (basal)not yet gradedNo reviewed efficacy summary in this indication
Insulin Glargine (Basaglar)ApprovedPeptideInsulin receptor (basal)not yet gradedNo reviewed efficacy summary in this indication
Insulin Glargine (Toujeo)ApprovedPeptideInsulin receptor (basal)not yet gradedNo reviewed efficacy summary in this indication
Insulin Glulisine (Apidra)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Insulin HumanApproved—Insulinnot yet gradedNo reviewed efficacy summary in this indication
Insulin Lispro (Humalog)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Insulin Lispro (Lyumjev)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Insulin NPH (Humulin N)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Pramlintide (Symlin)
ApprovedUS marketing discontinued
PeptideAmylin receptornot yet gradedNo reviewed efficacy summary in this indication
Dorzagliatin (Huatangning)
Phase 3(overall)
Small moleculeGlucokinase
Partial signal(overall)
No reviewed efficacy summary in this indication
PB-201
Phase 3(overall)
Small moleculeGlucokinase
Partial signal(overall)
No reviewed efficacy summary in this indication
Sotagliflozin (Inpefa)Phase 3Small moleculeSGLT1/2 (dual)not yet gradedNo reviewed efficacy summary in this indication
ZimislecelPhase 3Cell therapyPancreatic islet cells (VX-880 is a stem cell-derived therapy, not a small molecule drug), Pancreatic islet cell replacementnot yet gradedNo reviewed efficacy summary in this indication
Globalagliatin Hydrochloride
Phase 2(overall)
Small moleculeGlucokinase
Partial signal(overall)
No reviewed efficacy summary in this indication
IcovamenibPhase 2Small moleculeMeninnot yet gradedNo reviewed efficacy summary in this indication
HMS1005
Phase 1(overall)
Small moleculeGlucokinase
Partial signal(overall)
No reviewed efficacy summary in this indication

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow cadisegliatin to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
April 2027 (1)
Phase 3Type 1 DiabetesActive not recruiting
Est. primary completion 2027-04 · NCT06334133 · CT.gov ↗

Company guidance: topline data expected mid-2027 (vTv Therapeutics, 5 Nov 2026). “A total of 166 patients were randomized in the study and the Company expects to report topline results from the CATT1 study in mid-2027.” Source ↗

What to watch
June 2027 (1)
Phase 2Type 1 DiabetesRecruiting
Est. primary completion 2027-06 · NCT07616206 · CT.gov ↗
What to watch

See the full readout calendar ↗